ForeverLabs
ServicesProvidersScienceMission
Schedule your free consultation

Regenerative Medicine Insights

Clinical trials, aesthetic applications, regulatory updates, research studies, and industry insights from the world of regenerative medicine

K

Latest Articles

Active Filters:
Tag: Oct4 Suppression
generated-image-2.jpg
Clinical
Dec 2, 2025
1 min read
Pmc
Suppression of Oct4 by Germ Cell Nuclear Factor Restricts Pluripotency and Promotes Neural Stem Cell Development in the Early Neural Lineage
New findings reveal that the germ cell nuclear factor (GCNF) plays a crucial role in neural stem cell development by suppressing Oct4, a key gene for maintaining pluripotency. This regulation is vital for the transition of primitive neural stem cells to definitive ones, potentially unlocking new avenues for regenerative therapies in neurodegenerative diseases.
Oct4 SuppressionNeural Stem Cells

Stay in touch

Shop

Annual planLifetime planClient Login

Learn

ArticlesBlogPodcastFAQ

Careers

About usPrivacy policyPressTerms of Use

Questions

For physiciansPartner with usCareersContact us(888) 732-2375
ForeverLabs

FDA and Stem Cell Therapies

The U.S. Food and Drug Administration (FDA) regulates stem cell therapies as biological products to ensure their safety and efficacy. The FDA requires that stem cell therapies undergo rigorous clinical trials to demonstrate safety and effectiveness before approval. Patients considering stem cell treatments should consult with their healthcare providers about FDA-approved options and be cautious of unproven therapies that have not undergone proper regulatory review.